MARKET

NBP

NBP

NovaBridge Biosciences
NASDAQ
1.780
-0.020
-1.11%
After Hours: 1.750 -0.03 -1.69% 19:59 09/08 EDT
OPEN
1.790
PREV CLOSE
1.800
HIGH
1.825
LOW
1.750
VOLUME
127.00K
TURNOVER
--
52 WEEK HIGH
6.79
52 WEEK LOW
1.460
MARKET CAP
206.48M
P/E (TTM)
-2.7007
1D
5D
1M
3M
1Y
5Y
1D
NovaBridge Biosciences Strengthens Board with Appointment of Veteran Healthcare Executive
TipRanks · 17h ago
NovaBridge Biosciences Shareholders Vote to Remove Director at 2026 AGM
TipRanks · 17h ago
Weekly Report: what happened at NBP last week (0831-0904)?
Weekly Report · 1d ago
Weekly Report: what happened at NBP last week (0824-0828)?
Weekly Report · 08/31 10:17
Novabridge Biosciences Signals Promise Amid Funding Hurdles
TipRanks · 08/27 00:29
Weekly Report: what happened at NBP last week (0817-0821)?
Weekly Report · 08/24 10:17
NovaBridge Biosciences Price Target Maintained With a $9.00/Share by HC Wainwright & Co.
Dow Jones · 08/20 16:47
HC Wainwright & Co. Reiterates Buy on NovaBridge Biosciences, Maintains $9 Price Target
Benzinga · 08/20 16:38
More
About NBP
Novabridge Biosciences is a global biotechnology platform company. The Company combines deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. Its segments include oncology and ophthalmology. The oncology segment focuses on the research and development of precision immuno-oncology agents for the treatment of cancer. The ophthalmology segment focuses on research and development of ophthalmologic indications such as wet age-related macular degeneration (Wet AMD) and diabetic macular edema (DME). Its differentiated pipeline includes givastomig, a bispecific antibody (Claudin 18.2 x 4-1BB), and VIS-101, a bifunctional biologic, targeting VEGF-A and ANG2. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. VIS-101 targets VEGF-A and ANG-2 to provide more potent treatment benefits for patients with wet AMD and DME.

Webull offers NovaBridge Biosciences stock information, including NASDAQ: NBP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NBP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NBP stock methods without spending real money on the virtual paper trading platform.